Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) EBT (2022 - 2025)

Bioregenx (BRGX) has 4 years of EBT data on record, last reported at -$80565.0 in Q3 2025.

  • For Q3 2025, EBT rose 79.6% year-over-year to -$80565.0; the TTM value through Sep 2025 reached -$18.9 million, down 305.38%, while the annual FY2024 figure was -$23.1 million, 3936.27% down from the prior year.
  • EBT reached -$80565.0 in Q3 2025 per BRGX's latest filing, up from -$178345.0 in the prior quarter.
  • Across five years, EBT topped out at -$2191.0 in Q3 2022 and bottomed at -$18.4 million in Q4 2024.
  • Average EBT over 4 years is -$1.6 million, with a median of -$80565.0 recorded in 2025.
  • Peak YoY movement for EBT: tumbled 120016.01% in 2024, then soared 91.54% in 2025.
  • A 4-year view of EBT shows it stood at -$5535.0 in 2022, then plummeted by 176.77% to -$15319.0 in 2023, then crashed by 120016.01% to -$18.4 million in 2024, then skyrocketed by 99.56% to -$80565.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$80565.0 in Q3 2025, -$178345.0 in Q2 2025, and -$266854.0 in Q1 2025.